This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feld, G. K. Articles by Singh, B. N. Search for Related Content PubMed PubMed Citation Articles by Feld, G. K. Articles by Singh, B. N.

Circulation, Vol 74, 197-204, Copyright © 1986 by American Heart Association

ARTICLES

Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction

GK Feld, N Venkatesh and BN Singh

The electrophysiologic determinants of conversion and the prevention of atrial flutter are poorly defined. This issue was therefore investigated by evaluating the effects of the new class III antiarrhythmic drug d-sotalol and the class I antiarrhythmic drugs quinidine and lidocaine. Atrial flutter was reproducibly induced in the open-chest anesthetized dog with intercaval crush and rapid atrial pacing. In this preparation, intravenous d-sotalol restored sinus rhythm in 14 of 15 (93%) dogs, whereas quinidine converted nine of 15 (60%) and lidocaine two of 10 (20%). d-Sotalol prevented reinduction in eight (53%), whereas quinidine was effective in four (27%) and lidocaine in none (0%). In the atria, d-sotalol induced significant increases in effective refractory period (+32%; p less than .01), functional refractory period (+30%; p less than .01), conduction time at an atrial paced cycle length of 150 msec (+9%; p less than .05), and atrial flutter cycle length (+8%; p less than .01). Quinidine increased effective refractory period (+40%; p less than .01), functional refractory period (+27%; p less than .01), conduction time at sinus cycle length (+13%; p less than .01), conduction time at an atrial paced cycle length of 150 msec (+18%; p less than .01), and atrial flutter cycle length (+31%; p less than .01). Lidocaine decreased functional refractory period (-6%; p less than .05) while lengthening the atrial flutter cycle length (+13%; p less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. M. Rahme, G. Ungab, M. Wadhwa, F. Al-Kandari, B. Yao, A. Gupta, K. Lee, H.-Y. Kim, and G. K. Feld Electrophysiologic and Antiarrhythmic Effects of the New Class III Antiarrhythmic Drug KCB-328 in Experimental Canine Atrial Flutter Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 297 - 306. [Abstract] [PDF]

				D. Li, A. Benardeau, and S. Nattel Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation Circulation, July 4, 2000; 102(1): 104 - 112. [Abstract] [Full Text] [PDF]

				M. M. Rahme, B. Cotter, E. Leistad, M. K. Wadhwa, R. Mohabir, A. P. D. W. Ford, R. M. Eglen, and G. K. Feld Electrophysiological and Antiarrhythmic Effects of the Atrial Selective 5-HT4 Receptor Antagonist RS-100302 in Experimental Atrial Flutter and Fibrillation Circulation, November 9, 1999; 100(19): 2010 - 2017. [Abstract] [Full Text] [PDF]

				C.-T. Tai, S.-A. Chen, A.-N. Feng, W.-C. Yu, Y.-J. Chen, and M.-S. Chang Electropharmacologic Effects of Class I and Class III Antiarrhythmia Drugs on Typical Atrial Flutter : Insights Into the Mechanism of Termination Circulation, May 19, 1998; 97(19): 1935 - 1945. [Abstract] [Full Text] [PDF]

				A. A. Grace and A. J. Camm Quinidine N. Engl. J. Med., January 1, 1998; 338(1): 35 - 45. [Full Text] [PDF]

				B. S. Stambler, M. A. Wood, and K. A. Ellenbogen Antiarrhythmic Actions of Intravenous Ibutilide Compared With Procainamide During Human Atrial Flutter and Fibrillation : Electrophysiological Determinants of Enhanced Conversion Efficacy Circulation, December 16, 1997; 96(12): 4298 - 4306. [Abstract] [Full Text]

				C.-T. Tai, S.-A. Chen, C.-E. Chiang, S.-H. Lee, K.-C. Ueng, Z.-C. Wen, J.-L. Huang, Y.-J. Chen, W.-C. Yu, A.-N. Feng, et al. Characterization of Low Right Atrial Isthmus as the Slow Conduction Zone and Pharmacological Target in Typical Atrial Flutter Circulation, October 21, 1997; 96(8): 2601 - 2611. [Abstract] [Full Text]

				S. Sicouri, S. Moro, and M. V. Elizari d-Sotalol Induces Marked Action Potential Prolongation and Early Afterdepolarizations in M but Not Epicardial or Endocardial Cells of the Canine Ventricle Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 27 - 37. [Abstract] [PDF]

				D. Gallik, J. Altamirano, and B. N. Singh Review : Restoring Sinus Rhythm in Patients with Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(2): 135 - 144. [Abstract] [PDF]

				B. S. Stambler, M. A. Wood, K. A. Ellenbogen, K. T. Perry, L. K. Wakefield, and J. T. VanderLugt Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation Circulation, October 1, 1996; 94(7): 1613 - 1621. [Abstract] [Full Text]

				K. Mori, Y. Hara, T. Saito, Y. Masuda, and H. Nakaya Anticholinergic Effects of Class III Antiarrhythmic Drugs in Guinea Pig Atrial Cells : Different Molecular Mechanisms Circulation, June 1, 1995; 91(11): 2834 - 2843. [Abstract] [Full Text]